Перспективы использования препарата Спирива Респимат в клинической практике

1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2013 report is available on www.goldcopd.com
2. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
3. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
4. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–9.
5. Yohannes AM, Connolly M, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis 2013; 8: 117–25.
6. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010; 16: 97–105.
7. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
8. Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotopium. Eur Respir J 2002; 19: 209–16.
9. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 1: 217–24.
10. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.
11. Celli B, Wallack RZ, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.
12. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–48.
13. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
14. Decramer M, Celli B, Kesten S et al for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–8.
15. Troosters T, Celli B, Lystig T et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010; 36: 65–73.
16. Morice AH, Celli B, Kesten S et al. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010; 104: 1659–67.
17. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093–103.
18. Panos RJ. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease. Intern J COPD 2013; 8: 221–30.
19. Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft MistTM Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011; 4: 145–55.
20. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004; 283: 1–9.
21. Van Noord JA, Smeets JJ, Creemers JP et al. Delivery of fenoterol via Respimat, a novel «soft mist» inhaler. A randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients. Respiration 2000; 67: 672–8.
22. Longest PW, Hindle M, Choudhuri SD, Byron PR. Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. Aerosol Sci Technol 2007; 41: 952–73.
23. Longest PW, Hindle M, Choudhuri SD, Xi J. Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth-throat geometry. J Aerosol Sci 2008; 39: 572–91.
24. Newman SP, Pavia D, Morén F et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981; 36: 52–5.
25. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985; 88 (Suppl. 2): 152S–160S.
26. Stein SW, Gabrio BJ, Dalby RN et al. Understanding Throat Deposition During Cascade Impactor Testing. Respiratory Drug Delivery VII. Serentec, Raleigh, NC. 2000: 573–6.
27. Longest PW, Hindle M. Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths. J Aerosol Med Pulm Drug Deliv 2009; 22: 271–83.
28. Hochrainer D, Hölz H, Kreher C et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18: 273–82.
29. Khachikian D. VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist Executives. Ipratropium/Albuterol (Combivent® Respimat®) Abbreviated Review. 2012. Available from: http://www.pbm.va.gov/ClinicalGuidance/Abbreviated Reviews/Ipratropium-albuterol (CombiventRespimat). doc.  Accessed February 12, 2013.
30. Newman SP, Steed KP, Reader SJ et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996; 85: 960–4.
31. Newman SP, Brown J, Steed KP et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113: 957–63.
32. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005; 18: 264–72.
33. Brand P, Hederer B, Austen G et al. Higher lung deposition with Respimat Soft Mist inhaler than HFA–MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008; 3: 763–70.
34. Caillaud D, Le Merre C, Martinat Y et al. A dose-ranging study of tiotropium delivered via Respimat® Soft MistTM Inhaler or HandiHaler® in COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2: 559–65.
35. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 mg via Respimat and 18 mg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 2010; 104: 228–36.
36. ClinicalTrials.gov. 12 week comparison of 5 Mcg and 10 Mcg of Tiotropium/RespimatR, placebo and Ipratropium MDI in COPD. NCT00239473. 2010; http://clinicaltrials.gov/ct2/show/NCT00239473
37. ClinicalTrials.gov. 12 week comparison of 5 Mcg and 10 Mcg of Tiotropium/RespimatR, placebo and Ipratropium MDI in COPD. NCT00240435. 2010; http://clinicaltrials.gov/ct2/show/NCT00240435
38. ClinicalTrials.gov. Tiotropium/RespimatR one-year study. NCT00168844. 2010; http: clinicaltrials.gov/ct2/show/NCT00168844
39. ClinicalTrials.gov. Tiotropium/Respimat® one-year study. NCT00168831. 2010; http://clinicaltrials.gov/ct2/show/NCT00168831
40. ClinicalTrials.gov. Tiotropium/RespimatR one-year study in COPD. NCT00387088. 2010; http://clinicaltrials.gov/ct2/show/NCT00387088
41. Voshaar T, Lapidus R, Maleki-Yazdi R et al. A randomized study of tiotropium RespimatR Soft Mist inhaler vs ipratropium pMDI in COPD. Respir Med 2008; 102: 32–41.
42. Bateman E, Singh D, Smith D et al. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5: 197–208.
43. Bateman ED, Tashkin D, Siafakas N et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010; 104: 1460–72.
44. Abrahams R, Moroni-Zentgraf P, Ramsdell J et al. Safety and efficacy of the once-daily anticholinergic BEA 2180 compared to tiotropium in patients with COPD. Respir Med 2013; 107: 854–62.
45. Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 5: 367–73.
46. Asakura Y, Nishimura N, Maezawaet K et al. Effect of Switching Tiotropium HandiHaler to Respimat Soft Mist Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices. J Aerosol Med Pulm Drug Delivery 2013; 26: 41–5.
47. Feifel U, Wallenstein G, Rominger K-L et al. Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft MistTM Inhaler: findings from two dose-ranging studies in healthy men. Int J Chron Obstruct Pulmon Dis 2008; 3: 397–403.
48. Hodder R, Pavia D, Lee A, Bateman E. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist® Inhaler in COPD. Int J Chron Obstruct Pulmon Dis 2011; 6: 245–51.
49. Beasley R. Tiotropium Respimat increases the risk of mortality: pro. Eur Respir J 2013; 42: 584–9.
50. Bateman ED. Tiotropium Respimat increases the risk of mortality: con. Eur Respir J 2013; 42: 590–3.
51. Jenkins CR, Beasley R. Tiotropium Respimat increases risk of mortality. Thorax 2013; 68: 5–7.
52. Singh S, Loke YK, Enrigh PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215.
53. Lipworth BJ, Short PM. Explaining differential effects of tiotropium on mortality in COPD. Thorax 2013; 68: 589–90.
54. Tiotropium Respimat Pharmacokinetic Study in COPD (ClinicalTrials.gov Identifier: NCT01222533); http://www.clinicaltrials.gov/ (accessed 1 Sep 2013).
55. Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD. N Engl J Med 2013. DOI: 10.1056/NEJMoa1303342
56. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft MistTM Inhaler Int J Chron Obstruct Pulmon Dis 2009; 4: 381–90.
57. Schurmann W, Schmidtmann S, Moroni P et al. Respimat® Soft Mist Inhaler versus hydrofluoroalkane metered dose inhaler: Patient preference and satisfaction. Treat Respir Med 2005; 4: 53–61.
58. Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev 2005; 14: 109–16.
59. Kozma CM, Slaton TL, Monz BU et al. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med 2005; 4: 41–52.
60. Hodder R, Reese PR, Slaton T. Asthma patients prefer Respimat® Soft MistTM Inhaler to Turbuhaler®. Int J Chron Obstruct Pulmon Dis 2009; 4: 225–32.
61. Freytag F, Rau-Berger H, Glaab T et al. Respimat® Soft MistTM Inhaler preferred to Diskus by patients with COPD and/or asthma. Am J Respir Crit Care Med 2007; 175: A639.

С.Н.Авдеев

ФГУ НИИ пульмонологии Федерального медико-биологического агентства России